Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
TFOS is indicated for the treatment of pulmonary arterial hypertension
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Branded formulation business continues to perform well across domestic and export markets
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Subscribe To Our Newsletter & Stay Updated
